Literature DB >> 18698037

HER3 is a determinant for poor prognosis in melanoma.

Markus Reschke1, Daniela Mihic-Probst, Edward Htun van der Horst, Pjotr Knyazev, Peter J Wild, Markus Hutterer, Stefanie Meyer, Reinhard Dummer, Holger Moch, Axel Ullrich.   

Abstract

PURPOSE: The epidermal growth factor receptor family member HER3 is overexpressed in diverse human cancers and has been associated with poor prognosis in breast, lung, and ovarian cancer. However, the relevance of HER3 with regard to its prognostic significance and function in primary melanoma and metastases remains largely elusive. EXPERIMENTAL
DESIGN: HER3 protein expression was analyzed immunohistochemically using tissue microarrays of 130 primary melanoma and 87 metastases relative to established clinical variables. The possibility of an influence of HER3 on melanoma cell proliferation, migration, invasion, and chemotherapy-induced apoptosis was studied in human melanoma cell lines.
RESULTS: We show that HER3 is frequently expressed in malignant melanoma and metastases at elevated levels. High HER3 expression may serve as a prognostic marker because it correlates with cell proliferation, tumor progression, and reduced patient survival. Suppression of HER3 expression by RNA interference reduces melanoma cell proliferation, migration, and invasion in vitro. In addition, down-regulation of HER3 synergistically enhances dacarbazine-induced apoptosis. Moreover, monoclonal antibodies specific for the extracellular portion of HER3 efficiently block heregulin-induced proliferation, migration, and invasion of melanoma cell lines.
CONCLUSION: Our results provide novel insights into the role of HER3 in melanoma and point out new possibilities for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698037     DOI: 10.1158/1078-0432.CCR-08-0186

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  64 in total

1.  Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells.

Authors:  Raymond Reif; Alshaimaa Adawy; Nachiket Vartak; Jutta Schröder; Georgia Günther; Ahmed Ghallab; Marcus Schmidt; Wiebke Schormann; Jan G Hengstler
Journal:  J Biol Chem       Date:  2015-12-30       Impact factor: 5.157

2.  HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Authors:  Marcia R Campbell; Dhara Amin; Mark M Moasser
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Dennis H Kordish; Helene M Woyczesczyk; David Jeng; Karim Essani
Journal:  Virus Genes       Date:  2016-10-13       Impact factor: 2.332

4.  Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

Authors:  Martin Bezler; Jan G Hengstler; Axel Ullrich
Journal:  Mol Oncol       Date:  2012-07-20       Impact factor: 6.603

5.  A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Authors:  K Zhang; P Wong; L Zhang; B Jacobs; E C Borden; J C Aster; B Bedogni
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

6.  HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma.

Authors:  Hee Jin Lee; Joon-Yong Chung; Stephen M Hewitt; Eunsil Yu; Seung-Mo Hong
Journal:  Virchows Arch       Date:  2012-10-02       Impact factor: 4.064

Review 7.  The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Authors:  Dhara N Amin; Marcia R Campbell; Mark M Moasser
Journal:  Semin Cell Dev Biol       Date:  2010-09-09       Impact factor: 7.727

8.  EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Authors:  Gianluca Sala; Ilario Giovanni Rapposelli; Reza Ghasemi; Enza Piccolo; Sara Traini; Emily Capone; Cosmo Rossi; Angela Pelliccia; Annalisa Di Risio; Maurizia D'Egidio; Nicola Tinari; Raffaella Muraro; Stefano Iacobelli
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

9.  Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.

Authors:  Yassamine Lazrek; Olivier Dubreuil; Véronique Garambois; Nadège Gaborit; Christel Larbouret; Christophe Le Clorennec; Gaelle Thomas; Wilhem Leconet; Marta Jarlier; Martine Pugnière; Nadia Vié; Bruno Robert; Céline Monnet; Khalil Bouayadi; Hakim Kharrat; Philippe Mondon; André Pèlegrin; Thierry Chardès
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

Review 10.  Biomarkers in melanoma.

Authors:  H Gogas; A M M Eggermont; A Hauschild; P Hersey; P Mohr; D Schadendorf; A Spatz; R Dummer
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.